Related Experiment Video
Updated: Jun 3, 2026
09:33
Quantitative 3D In Silico Modeling (q3DISM) of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease
Published on: December 26, 2016
Epigenetic mechanisms in Alzheimer's disease
M Daniilidou1, M Koutroumani, M Tsolaki
1Department of Chemistry, Aristotle University, Thessaloniki, Greece.
Current Medicinal Chemistry
|April 7, 2011
Summary
Epigenetic changes like DNA methylation and histone acetylation may drive Late Onset Alzheimer's Disease (LOAD). Targeting these epigenetic mechanisms offers potential new treatments for dementia and cognitive decline in Alzheimer's patients.
Area of Science:
- Neuroscience
- Genetics
- Epigenetics
Background:
- Alzheimer's disease (AD) is a leading neurodegenerative disorder in individuals over 65.
- Late Onset Alzheimer's Disease (LOAD), comprising over 95% of cases, is a complex multifactorial disorder.
- While some genes are implicated, they explain only a fraction of LOAD cases.
Purpose of the Study:
- To review recent advances in understanding epigenetic mechanisms in LOAD.
- To explore the role of chromatin remodeling and epigenomic alterations in neurodegeneration.
- To discuss potential therapeutic strategies targeting epigenetic modifications.
Main Methods:
- Literature review of recent studies on epigenetics and Alzheimer's disease.
- Analysis of research on DNA methylation and histone acetylation in AD pathogenesis.
- Synthesis of findings on synaptic dysfunction and cognitive decline linked to epigenetic changes.
Main Results:
- Epigenetic alterations, including aberrant DNA methylation and histone acetylation, are increasingly linked to LOAD.
- These epigenetic changes can affect the transcription of key genes involved in AD, such as APP.
- Synaptic dysfunction and cognitive decline are associated with common epigenetic modifications.
Conclusions:
- Epigenetic mechanisms play a significant role in the pathogenesis of Late Onset Alzheimer's Disease.
- Targeting the epigenomic machinery presents a promising avenue for novel therapeutic interventions.
- Further research into epigenetic modifications could lead to effective treatments for AD-related dementia.
Related Concept Videos
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
01:37Epigenetic Regulation
Epigenetic changes alter the physical structure of the DNA without changing the genetic sequence and often regulate whether genes are turned on or off. This regulation ensures that each cell produces only proteins necessary for its function. For example, proteins that promote bone growth are not produced in muscle cells. Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
X-chromosome...
X-chromosome...